TargaZyme, a biotech company, is on a mission to revolutionize cancer treatment by enhancing the delivery of stem cells to diseased organs. CEO Koh is looking to bring this innovative technology to Singapore, aiming to benefit patients in the region. Collaborating with cord-blood banks in Asia, TargaZyme is in the process of selecting the optimal partner to maximize the impact of their technology and drive significant revenues. Stay tuned for updates on how TargaZyme’s advancements in Cancer Stem Cells in Therapy could shape the future of cancer treatment.
Read more about this — here
